Why this is important: Three vaccines are routinely recommended for ages 11-12: MenACWY to protect against meningococcal disease, Human Papillomavirus (HPV) to protect against HPV-associated cancers, and Tdap to protect against whooping cough. A revised Healthcare Effectiveness Data and Information Set (HEDIS) measure implemented in 2017 assesses the receipt of Tdap, MenACWY, and HPV vaccines by age 13 years in both females and males enabling health plans to evaluate their performance in administering these vaccines to adolescents. The 13-17 age group serves as an indicator of compliance with the Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for teens and adolescents at ages 11-12. To optimize protection of adolescents against vaccine-preventable diseases, including HPV-associated cancers, it is important for clinicians to consistently recommend and co-administer Tdap, MenACWY, and HPV vaccines at 11-12 years. Additionally, data for adolescent vaccination coverage among the “catch-up” 13-17 age group are used to identify groups of adolescents at risk of vaccine-preventable diseases and to determine what additional efforts are needed to increase coverage.
Definition: Percent of youth 13-17 years of age with complete vaccination records on file in the WA Immunization Information System (WAIIS) (1-Tdap, 1-MCV, 1-HPV,).
Data Source: WA Immunization Information System. http://www.doh.wa.gov/DataandStatisticalReports/HealthBehaviors/Immunization/ImmunizationInformationSystem. https://www.cdc.gov/mmwr/volumes/65/wr/mm6533a4.htm